Journal article
Comparing 5-Year and Lifetime Risks of Breast Cancer using the Prospective Family Study Cohort
RJ MacInnis, JA Knight, WK Chung, RL Milne, AS Whittemore, R Buchsbaum, Y Liao, N Zeinomar, GS Dite, MC Southey, D Goldgar, GG Giles, AW Kurian, IL Andrulis, EM John, MB Daly, SS Buys, KA Phillips, JL Hopper, MB Terry
Journal of the National Cancer Institute | OXFORD UNIV PRESS INC | Published : 2021
DOI: 10.1093/jnci/djaa178
Abstract
Background: Clinical guidelines often use predicted lifetime risk from birth to define criteria for making decisions regarding breast cancer screening rather than thresholds based on absolute 5-year risk from current age. Methods: We used the Prospective Family Cohort Study of 14 657 women without breast cancer at baseline in which, during a median follow-up of 10 years, 482 women were diagnosed with invasive breast cancer. We examined the performances of the International Breast Cancer Intervention Study (IBIS) and Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) risk models when using the alternative thresholds by comparing predictions based on 5..
View full abstractRelated Projects (5)
Grants
Awarded by National Center for Advancing Translational Sciences
Funding Acknowledgements
This work was primarily supported by a grant from the US National Institute of Health (RO1CA159868). Additionally, the cohorts were supported through additional resources. The Australian Breast Cancer Family Registry was supported by the Australian National Health and Medical Research Council, the New South Wales Cancer Council, the Victorian Health Promotion Foundation, the Victorian Breast Cancer Research Consortium, Cancer Australia, and the National Breast Cancer Foundation. The 6 sites of the Breast Cancer Family Registry were supported by grants from the US National Cancer Institute (UM1 CA164920 and U01CA164920). This work was also supported by grants to the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) and the kConFab FollowUp Study from Cancer Australia (809195 and 1100868), the Australian National Breast Cancer Foundation (IF 17 kConFab), the National Health and Medical Research Council (454508, 288704, and 145684), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. K-AP is a Practitioner Fellow of the Australian National Breast Cancer Foundation (PRAC-17-004). JLH and MCS are Senior Principal and Senior Research Fellows of the National Health and Medical Research Council, Australia, respectively. MBT also thanks the Breast Cancer Research Foundation for support.